Akari Therapeutics Plc Stock Price, News & Analysis

Akari Therapeutics (NASDAQ: AKTX) released a Virtual Investor “What This Means” segment on Dec. 18, 2025 featuring President and CEO Abizer Gaslightwala.

The video covers Akari’s spliceosome-modulating payload PH1, new preclinical data for lead ADC AKTX-101 in hard-to-treat KRAS‑mutant pancreatic cancer, and the company’s plan to advance AKTX-101 into clinical testing by late 2026/early 2027. The segment is available to watch online.

Akari Therapeutics (Nasdaq: AKTX) announced a financing expected to raise approximately $5.0 million through a registered direct offering and concurrent private placement of a total of 12,607,487 ADSs (plus matching unregistered warrants).

The registered direct portion comprises 10,043,774 ADSs and Series G warrants at a combined price of $0.3883 per ADS and warrant; the private placement covers 2,563,713 pre-funded warrants and warrants at a combined price of $0.4041. Existing note holders will convert ~$2.50 million of debt into pre-funded warrants and warrants. More than $1 million of new cash comes from directors, officers and management. Proceeds will fund R&D, working capital and general corporate purposes; closing expected on or about Dec 17, 2025.

Akari Therapeutics (Nasdaq: AKTX) reported preclinical data showing its Trop2-targeting ADC AKTX-101 has single-digit nanomolar cytotoxic potency in K-Ras G12V pancreatic ductal adenocarcinoma (PDAC) cell lines and outperformed daraxonrasib in multiple PDAC cell lines.

The release notes Trop2 is highly expressed in K-Ras mutated PDAC, AKTX-101 carries a spliceosome-modulating payload PH1, and the company expects a first-in-human trial in late 2026 with preliminary safety and efficacy results in 2027.

Akari Therapeutics (NASDAQ: AKTX) published a new CEO Corner on Dec 4, 2025 with a corporate update from CEO Abizer Gaslightwala.

The company described its ADC payload platform built around a novel PH1 payload that targets the spliceosome and reported a unique preclinical efficacy and safety profile. Akari named its lead candidate AKTX-101, a Trop2-directed ADC with a proprietary linker that delivers the PH1 payload to tumors. The company is initiating IND-enabling studies and plans to advance AKTX-101 into clinical trials in 4Q 2026.

Akari Therapeutics (Nasdaq: AKTX) announced on Nov 25, 2025 that a new CEO Corner segment is published on the company website. In the video, CEO Abizer Gaslightwala reviews Akari’s innovation in antibody drug conjugates (ADCs), highlights the company’s novel PH1 payload and its dual mechanism of action, and discusses the capabilities of Akari’s next‑generation ADC discovery platform. The segment reiterates the company’s mission to advance differentiated therapies for patients and is available for viewing on the company website.

Akari Therapeutics (Nasdaq: AKTX) announced on November 18, 2025 the appointment of Kameel D. Farag as Interim Chief Financial Officer; he joined Akari last month.

Mr. Farag brings >20 years of biotech finance and operations experience, including $170M+ capital raised across his career, securing $150M+ in financing at Aspen Neuroscience, supporting $1B+ revenue growth at Ionis, and leading international finance roles at Amgen. The company said his experience in corporate finance, M&A, and operational build-outs will support acceleration of Akari’s ADC platform and advancement of its lead asset toward the clinic.

Akari Therapeutics (NASDAQ: AKTX) presented preclinical immuno-oncology data for its novel spliceosome-targeting ADC payload, PH1, at the 40th Annual SITC Meeting on November 10, 2025. The data show PH1 drives cancer cell cytotoxicity and broad immune activation, including macrophage polarization, neutrophil increases, B-cell/IgM expansion, and gamma-delta T-cell expansion when combined with anti-PD1.

In an immune-competent HER2-positive colon tumor model, Trastuzumab-PH1 + anti-PD1 produced complete responses in 74% vs 42% (p<0.05) compared with Kadcyla + anti-PD1. Akari is advancing lead candidate AKTX-101 (Trop2-PH1) into IND-enabling studies and will host a live webcast on Nov 18, 2025 at 11:00 AM ET.

Akari Therapeutics (Nasdaq: AKTX) announced its SITC 40 abstract and presentations on November 7 and 9, 2025 describing preclinical immune mechanism data for its novel ADC payload PH1.

The company reports that a Trastuzumab–PH1 ADC produced higher rates of complete colon-tumor regressions versus a comparator microtubule-inhibitor ADC when combined with an anti‑PD‑1 checkpoint inhibitor. The PH1 combination is attributed to neoantigen-driven immune activation, antigen-presenting cell, B-cell and T-cell engagement, and expansion of tumor‑killing gamma‑delta T cells. Poster and oral presentation details and times are provided for the SITC Annual Meeting.

Akari Therapeutics (Nasdaq: AKTX) announced on October 30, 2025 the formation of a Scientific Advisory Board and the inaugural appointment of Dr. Sara A. Hurvitz, MD, FACP.

Dr. Hurvitz is described as an international oncology expert with extensive clinical trial leadership and specific experience in antibody drug conjugates (ADCs) and breast cancer therapies. She currently holds leadership roles at the University of Washington School of Medicine and Fred Hutchinson Cancer Center. The company noted its ADC pipeline includes AKTX-101 (Trop2 ADC with PH1 payload) and future programs such as AKTX-102.